Femarelle
Not sure how effective for us, but has shown to be effective on post-menopausal women I believe.
Recent studies prove that Femarelle®:
Provided fast acting relief (average 5-7 days).
Alleviated menopausal symptoms in 3 out of 4 patients.
Relieved hot flashes in 76% of the patients.
Improved headaches in 68% of the patients.
Improved joint and muscle discomfort in 70% of patients.
Promoted Bone Health.
Had no effect on the breast tissue and the uterus.
Had no reported adverse events.
Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss.
Se-cure Pharmaceuticals has developed a chemical composition working as a Selective Estrogen Receptor Modulator- a SERM, in the body. The estrogen receptor bondage allows the substance to provide both menopausal symptoms relief and prevents the bone loss process, through osteoblast activity, without affecting the breast and uterine tissues.
The product developed is called Femarelle™, it is a product derived through a unique enzymatic procedure that creates a specific biochemical composition proven to combine the treatment of menopausal symptom relief and bone loss.
Rich in scientific backup proving its high efficacy and safety of use, Femarelle™ represents the next generation treatment for the management of menopause.
Femarelle™ enjoys the same efficacy as HT in the relief of menopausal symptoms, providing relief of the main symptoms, such as hot flashes, night sweats etc. for 75% of the women.
At the onset of menopause, following the decrease of estrogen in the body, the bone undergoes a yearly decline of BMD of 2-3% per year in the 5-7 years following menopause, leading to the development of osteoporosis, a disease affecting 1 in 2 postmenopausal women today.
As a product that incorporates the treatment of menopause and bone health, Femarelle™ serves marketing wise two important fronts. Most women reaching menopause (80%) go to their physician following the onset of the encumbering symptoms encountered in this stage of their life, from the point of view of the health-care provider providing a product with a high efficacy for the symptoms but with the added advantage of providing an added protection of their bone health, is an ideal solution. The second front that is achieved deals with the physician psyche; most were used to provide hormonal treatment as the ideal solution for the management of menopause, Femarelle™ as a SERM that acts through the same mechanism of estrogen receptors, enables to introduce Femarelle™ as the next generation treatment for the management of menopause, providing the same efficacy but as the next generation Femarelle™ provides a high safety profile, decreasing the symptoms and maintaining bone health without affecting the sensitive tissues of the breast and uterus.
As an OTC derived from a natural source, Femarelle™ is perceived by the consumer as a safe and preferable option.
Providing a sound scientific backup, high efficacy and with no side effects Femarelle™ is welcomed by the physician and is easily taken by the patient for the long-term treatment of menopause and the prevention of osteoporosis.
Articles
Menopause. 10(6):522-525, November 2003.
Yoles, Israel MD 1; Yogev, Yariv MD 2; Frenkel, Yair MD 1; Nahum, Ravit MD 2; Hirsch, Michael MD 2; Kaplan, Boris MD 2
Abstract:
Objective: To evaluate the efficacy of Tofupill/Femarelle (DT56a), a novel phyto-selective estrogen receptor modulator (SERM), in preserving bone mineral density (BMD) in postmenopausal women.
Design: The study sample consisted of 98 healthy, postmenopausal women who were randomly allocated, on a double-blind basis, to receive either 644 mg/d DT56a (study group) or 344 mg/d DT56a supplemented with calcium (low-dose group) for 12 months. Each participant was assessed with a comprehensive health questionnaire, a detailed physical, and laboratory and pelvic sonogram examinations at entry and every 3 months thereafter. BMD was assessed by dual-energy x-ray absorptiometry (Lunar) of the lumbar spine and femoral neck before the study began and after 12 months of treatment.
Results: After 12 months of treatment, BMD had increased in the study group by 3.6% in the lumbar spine (P = 0.039) and by 2.0% in the femoral neck (NS). In the low-dose group, BMD had decreased in the lumbar spine by 0.6% (NS) and by 0.6% in the femoral neck (NS). Comparison of the change in bone density between the groups yielded a significant difference for the lumbar spine (P = 0.037). Neither group showed a change in endometrial thickness and sex hormone levels nor reported any side effects of treatment.
Conclusions: Tofupill treatment in postmenopausal women increases BMD without unwanted estrogenic effect. Tofupill appears to be a promising phyto-SERM for the prevention of postmenopausal osteoporosis.
(C)2003The North American Menopause Society
DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus.Somjen D, Yoles I.Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center, 64239, Tel-Aviv, Israel. [email protected]
The novel natural product DT56a (Tofupill/Femarelle), derived from soybean, has been shown to relieve menopausal vasomotor symptoms and to increase bone mineral density with no effect on sex steroid hormone levels or endometrial thickness. In the present study, we compared the effects of DT56a and estradiol-17beta (E2) on bone and cartilage (Ep) of immature or ovariectomized female rats, by measuring the changes in the specific activity of the BB isozyme of creatine kinase (CK). Single short-term injection of high doses of DT56a induced estrogenic activity in bones and uterus similar to that of E2. When administered in multiple oral doses, DT56a stimulated skeletal tissues similarly to E2, but whereas E2 increased CK specific activity in the uterus, DT56a did not. The selective estrogen receptor modulator (SERM) raloxifene (Ral) blocked the stimulation of CK by either DT56a or by E2 in all tissues tested. Our findings suggest that DT56a acts as a selective estrogen receptor modulator stimulating skeletal tissues without affecting the uterus. The effect of DT56a on other systems, such as the vascular and the central nervous system, are currently under investigation.
PMID: 12943748 [PubMed - indexed for MEDLINE]
bb
Not sure how effective for us, but has shown to be effective on post-menopausal women I believe.
Recent studies prove that Femarelle®:
Provided fast acting relief (average 5-7 days).
Alleviated menopausal symptoms in 3 out of 4 patients.
Relieved hot flashes in 76% of the patients.
Improved headaches in 68% of the patients.
Improved joint and muscle discomfort in 70% of patients.
Promoted Bone Health.
Had no effect on the breast tissue and the uterus.
Had no reported adverse events.
Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss.
Se-cure Pharmaceuticals has developed a chemical composition working as a Selective Estrogen Receptor Modulator- a SERM, in the body. The estrogen receptor bondage allows the substance to provide both menopausal symptoms relief and prevents the bone loss process, through osteoblast activity, without affecting the breast and uterine tissues.
The product developed is called Femarelle™, it is a product derived through a unique enzymatic procedure that creates a specific biochemical composition proven to combine the treatment of menopausal symptom relief and bone loss.
Rich in scientific backup proving its high efficacy and safety of use, Femarelle™ represents the next generation treatment for the management of menopause.
Femarelle™ enjoys the same efficacy as HT in the relief of menopausal symptoms, providing relief of the main symptoms, such as hot flashes, night sweats etc. for 75% of the women.
At the onset of menopause, following the decrease of estrogen in the body, the bone undergoes a yearly decline of BMD of 2-3% per year in the 5-7 years following menopause, leading to the development of osteoporosis, a disease affecting 1 in 2 postmenopausal women today.
As a product that incorporates the treatment of menopause and bone health, Femarelle™ serves marketing wise two important fronts. Most women reaching menopause (80%) go to their physician following the onset of the encumbering symptoms encountered in this stage of their life, from the point of view of the health-care provider providing a product with a high efficacy for the symptoms but with the added advantage of providing an added protection of their bone health, is an ideal solution. The second front that is achieved deals with the physician psyche; most were used to provide hormonal treatment as the ideal solution for the management of menopause, Femarelle™ as a SERM that acts through the same mechanism of estrogen receptors, enables to introduce Femarelle™ as the next generation treatment for the management of menopause, providing the same efficacy but as the next generation Femarelle™ provides a high safety profile, decreasing the symptoms and maintaining bone health without affecting the sensitive tissues of the breast and uterus.
As an OTC derived from a natural source, Femarelle™ is perceived by the consumer as a safe and preferable option.
Providing a sound scientific backup, high efficacy and with no side effects Femarelle™ is welcomed by the physician and is easily taken by the patient for the long-term treatment of menopause and the prevention of osteoporosis.
Articles
Menopause. 10(6):522-525, November 2003.
Yoles, Israel MD 1; Yogev, Yariv MD 2; Frenkel, Yair MD 1; Nahum, Ravit MD 2; Hirsch, Michael MD 2; Kaplan, Boris MD 2
Abstract:
Objective: To evaluate the efficacy of Tofupill/Femarelle (DT56a), a novel phyto-selective estrogen receptor modulator (SERM), in preserving bone mineral density (BMD) in postmenopausal women.
Design: The study sample consisted of 98 healthy, postmenopausal women who were randomly allocated, on a double-blind basis, to receive either 644 mg/d DT56a (study group) or 344 mg/d DT56a supplemented with calcium (low-dose group) for 12 months. Each participant was assessed with a comprehensive health questionnaire, a detailed physical, and laboratory and pelvic sonogram examinations at entry and every 3 months thereafter. BMD was assessed by dual-energy x-ray absorptiometry (Lunar) of the lumbar spine and femoral neck before the study began and after 12 months of treatment.
Results: After 12 months of treatment, BMD had increased in the study group by 3.6% in the lumbar spine (P = 0.039) and by 2.0% in the femoral neck (NS). In the low-dose group, BMD had decreased in the lumbar spine by 0.6% (NS) and by 0.6% in the femoral neck (NS). Comparison of the change in bone density between the groups yielded a significant difference for the lumbar spine (P = 0.037). Neither group showed a change in endometrial thickness and sex hormone levels nor reported any side effects of treatment.
Conclusions: Tofupill treatment in postmenopausal women increases BMD without unwanted estrogenic effect. Tofupill appears to be a promising phyto-SERM for the prevention of postmenopausal osteoporosis.
(C)2003The North American Menopause Society
DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus.Somjen D, Yoles I.Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center, 64239, Tel-Aviv, Israel. [email protected]
The novel natural product DT56a (Tofupill/Femarelle), derived from soybean, has been shown to relieve menopausal vasomotor symptoms and to increase bone mineral density with no effect on sex steroid hormone levels or endometrial thickness. In the present study, we compared the effects of DT56a and estradiol-17beta (E2) on bone and cartilage (Ep) of immature or ovariectomized female rats, by measuring the changes in the specific activity of the BB isozyme of creatine kinase (CK). Single short-term injection of high doses of DT56a induced estrogenic activity in bones and uterus similar to that of E2. When administered in multiple oral doses, DT56a stimulated skeletal tissues similarly to E2, but whereas E2 increased CK specific activity in the uterus, DT56a did not. The selective estrogen receptor modulator (SERM) raloxifene (Ral) blocked the stimulation of CK by either DT56a or by E2 in all tissues tested. Our findings suggest that DT56a acts as a selective estrogen receptor modulator stimulating skeletal tissues without affecting the uterus. The effect of DT56a on other systems, such as the vascular and the central nervous system, are currently under investigation.
PMID: 12943748 [PubMed - indexed for MEDLINE]
bb